EUVIMEDEUVIMED entdecken
Systematische ÜbersichtVergleichsstudie

Oral β‐Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point‐Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones

Ashlan J Kunz Coyne iD, Jeannette Bouchard iD, Spencer H Durham iD, Amy Y Kang iD, Kinsey M Johannemann iD, W Justin Moore iD, Kevin Nguyen iD, James Sanders iD, Colter Sheveland iD, Grant Stimes iD, Trang Trinh iD, Elizabeth W Covington iD und 1 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-03 · 46 (3)

DOI: 10.1002/phar.70118 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 15.02.2026. Verfasst von Ashlan J Kunz Coyne und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Kentucky, College of Pharmacy, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Anti-Bacterial Agents, beta-Lactams, Fluoroquinolones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rising resistance and toxicity concerns with fluoroquinolones (FQs) and trimethoprim/sulfamethoxazole (TMP/SMX) have prompted interest in oral β‐lactams as alternatives for complicated urinary tract infections (cUTIs). This review evaluates the effectiveness, safety, and pharmacokinetic (PK) considerations of oral β‐lactams compared to FQs and TMP/SMX in these clinical contexts. A structured point‐counterpoint discussion explores their role in antimicrobial stewardship and patient‐centered therapy.

Methods

A systematic PubMed search identified studies published between January 2000 and December 2025. Eligible studies included randomized trials and observational cohort studies evaluating clinical effectiveness, microbiological outcomes, or safety of oral β‐lactams for cUTIs or bacteremic UTI compared with FQs or TMP/SMX. Outcomes of interest included treatment success, recurrence, adverse events, and PK considerations. Excluded studies involved special populations, nontraditional agents, or infections outside the scope of cUTI. Data were synthesized narratively due to heterogeneity in study design and outcome reporting.

Results

Seventeen observational studies met the inclusion criteria. Oral β‐lactams demonstrated comparable effectiveness to FQs and TMP/SMX for cUTIs, including bacteremic UTI, when dosed appropriately. Oral β‐lactams with high oral bioavailability (e.g., cephalexin, cefpodoxime, cefuroxime, amoxicillin/clavulanate), showed success rates exceeding 90%, but recurrence was higher when underdosed. Oral β‐lactams had lower adverse event rates (1.3%) compared to FQs (2.3%) and TMP/SMX (5.7%), but may carry limitations including frequent dosing, variable bioavailability, and susceptibility testing challenges.

Conclusions

Although not traditionally recognized as first‐line therapy, select oral β‐lactams demonstrated effectiveness comparable to FQs or TMP/SMX for cUTIs and bacteremic UTI and can serve as effective alternatives in appropriately selected patients. When optimally dosed, these β‐lactams achieve comparable outcomes with favorable safety profiles and antimicrobial stewardship advantages. Randomized trials are needed to confirm these observational findings and to better define optimal dosing strategies and shorter treatment durations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsAnti-Bacterial Agentsbeta-LactamsFluoroquinolonesTrimethoprim, Sulfamethoxazole Drug CombinationHumansAdministration, Oral

Stichwörter der Autor:innen

antibacterial agentsbeta‐lactamsfluoroquinolonessulfamethoxazole drug combinationtrimethoprimurinary tract infections

Substanzen

Anti-Bacterial Agentsbeta-LactamsFluoroquinolonesTrimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • University of Kentucky, College of Pharmacy, Lexington, Kentucky, USA.
  • Duke Antimicrobial Stewardship Outreach Network (DASON), Durham, North Carolina, USA.
  • Auburn University, Harrison College of Pharmacy, Auburn, Alabama, USA.
  • Chapman University, School of Pharmacy, Irvine, California, USA.
  • Huntsville Hospital, Huntsville, Alabama, USA.
  • Northwestern Medicine, Chicago, Illinois, USA.

ORCID-Profile: Ashlan J Kunz Coyne, Jeannette Bouchard, Spencer H Durham, Amy Y Kang, Kinsey M Johannemann, W Justin Moore, Kevin Nguyen, James Sanders, Colter Sheveland, Grant Stimes, Trang Trinh, Elizabeth W Covington

Zitieren

APA

Kunz Coyne, A. J., Bouchard, J., Durham, S. H., Kang, A. Y., Johannemann, K. M., Moore, W. J., Nguyen, K., Sanders, J., Sheveland, C., Stimes, G., Trinh, T., Covington, E. W., & ACCP Infectious Disease Practice and Research Network (PRN) Research Committee (2026). Oral β‐Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point‐Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(3). https://doi.org/10.1002/phar.70118

Vancouver

Kunz Coyne AJ, Bouchard J, Durham SH, Kang AY, Johannemann KM, Moore WJ, et al. Oral β‐Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point‐Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(3). doi:10.1002/phar.70118

BibTeX
@article{KunzCoyne2026,
  author = {Kunz Coyne, Ashlan J and Bouchard, Jeannette and Durham, Spencer H and Kang, Amy Y and Johannemann, Kinsey M and Moore, W Justin and Nguyen, Kevin and Sanders, James and Sheveland, Colter and Stimes, Grant and Trinh, Trang and Covington, Elizabeth W and ACCP Infectious Disease Practice and Research Network (PRN) Research Committee, ACCP Infectious Disease Practice and Research Network (PRN) Research Committee},
  title = {Oral β‐Lactams for Complicated Urinary Tract Infections: A Systematic Review and Point‐Counterpoint Comparison With Trimethoprim/Sulfamethoxazole and Fluoroquinolones},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1002/phar.70118}
}
Kostenlos starten →